Cucurbitacin-I (JSI-124) activates the JNK/c-Jun signaling pathway independent of apoptosis and cell cycle arrest in B Leukemic Cells

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Ishdorj, Ganchimeg ^a,b   Johnston, James B ^a,b   Gibson, Spencer B ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Angiogenesis; c Jun; JSI 124; VEGF

Indexed keywords

ANTILEUKEMIC AGENT; CUCURBITACIN I; DNA; JSI 124; LIPOCORTIN 5; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROPIDIUM IODIDE; PROTEIN C JUN; RECOMBINANT VASCULOTROPIN; SMALL INTERFERING RNA; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; VASCULOTROPIN; X LINKED INHIBITOR OF APOPTOSIS; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; STAT3 PROTEIN, HUMAN; TRITERPENE; TUMOR PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; BINDING SITE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL STRAIN BJAB; CELL STRAIN I 83; CELL STRAIN NALM 6; CONTROLLED STUDY; DNA CONTENT; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOMA CELL LINE; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STAINING; WESTERN BLOTTING; BIOSYNTHESIS; BURKITT LYMPHOMA; CELL CYCLE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; ONCOGENE; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN BINDING; PROTEIN PROCESSING; TUMOR CELL LINE;

APOPTOSIS; BURKITT LYMPHOMA; CELL CYCLE; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, JUN; HUMANS; LEUKEMIA, B-CELL; MAP KINASE KINASE 4; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-JUN; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION, GENETIC; TRITERPENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79959424651     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-268     Document Type: Article

References (42)

1. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Research 2003, 63(6):1270-9.
2. Chen JC, Chiu MH, Nie RL, Cordell GA, Qiu SX. Cucurbitacins and cucurbitane glycosides: structures and biological activities. Natural Product Reports 2005, 22(3):386-99. 10.1039/b418841c, 16010347.
3. Lee DH, Iwanski GB, Thoennissen NH. Cucurbitacin: ancient compound shedding new light on cancer treatment. Scientific World Journal 2010, 10:413-8.
4. Jing N, Tweardy DJ. Targeting Stat3 in cancer therapy. Anticancer Drugs 2005, 16(6):601-7. 10.1097/00001813-200507000-00002, 15930886.
5. Molavi O, Ma Z, Hamdy S, Lai R, Lavasanifar A, Samuel J. Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model. Immunology and Cell Biology 2008, 86(6):506-14. 10.1038/icb.2008.27, 18392040.
6. Su Y, Li G, Zhang X, Gu J, Zhang C, Tian Z, Zhang J. JSI-124 inhibits glioblastoma multiforme cell proliferation through G(2)/M cell cycle arrest and apoptosis augment. Cancer Biology and Therapy 2008, 7(8):1243-9. 10.4161/cbt.7.8.6263, 18487947.
7. Ishdorj G, Johnston JB, Gibson SB. Inhibition of constitutive activation of STAT3 by curcurbitacin-I (JSI-124) sensitized human B-leukemia cells to apoptosis. Molecular Cancer Therapeutics 2010, 9(12).
8. Graness A, Poli V, Goppelt-Struebe M. STAT3-independent inhibition of lysophosphatidic acid-mediated upregulation of connective tissue growth factor (CTGF) by cucurbitacin I. Biochemical Pharmacology 2006, 72(1):32-41. 10.1016/j.bcp.2006.04.001, 16707113.
9. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000, 103(2):239-52. 10.1016/S0092-8674(00)00116-1, 11057897.
10. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001, 410:37-40. 10.1038/35065000, 11242034.
11. Rosen LS. VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist 2005, 10(6):382-91. 10.1634/theoncologist.10-6-382, 15967832.
12. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000, 407(6801):249-57. 10.1038/35025220, 11001068.
13. Chiarug V, Ruggiero M, Magnelli L. Angiogenesis and the unique nature of tumor matrix. Molecular Biotechnology 2002, 21(1):85-90. 10.1385/MB:21:1:085, 11989661.
14. Chien MH, Ku CC, Johansson G, Chen MW, Hsiao M, Su JL, Inoue H, Hua KT, Wei LH, Kuo ML. Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway. Carcinogenesis 2009, 30(12):2005-13. 10.1093/carcin/bgp244, 19825968.
15. Molica S. Angiogenesis in B-cell chronic lymphocytic leukemia: methods of study, clinical significance and prognostic implications. Leukemia and Lymphoma 2001, 42(4):603-7. 10.3109/10428190109099320, 11697488.
16. Lee J, Park SY, Lee EK, Park CG, Chung HC, Rha SY, Kim YK, Bae GU, Kim BK, Han JW, Lee HY. Activation of hypoxia-inducible factor-1alpha is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression. Clinical Cancer Research 2006, 12(21):6351-8. 10.1158/1078-0432.CCR-06-1252, 17085645.
17. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand Holash SJ. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407(6801):242-8. 10.1038/35025215, 11001067.
18. Krejsgaard T, Vetter-Kauczok CS, Woetmann A, Lovato P, Labuda T, Eriksen KW, Zhang Q, Becker JC, Ødum N. Jak3-and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia 2006, 20(10):1759-66. 10.1038/sj.leu.2404350, 16932349.
19. Kumar SA, Hu X, Brown M, Kuschak B, Hernandez TA, Johnston JB, Gibson SB. Lysophosphatidic acid receptor expression in chronic lymphocytic leukemia leads to cell survival mediated though vascular endothelial growth factor expression. Leukemia and Lymphoma 2009, 50(12):2038-48. 10.3109/10428190903275586, 19860625.
20. Shibata A, Nagaya T, Imai T, Funahashi H, Nakao A, Seo H. Inhibition of NF-kappaB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells. Breast Cancer Research and Treatment 2002, 73(3):237-43. 10.1023/A:1015872531675, 12160329.
21. Hu X, Mendoza FJ, Sun J, Banerji V, Johnston JB, Gibson SB. Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies. Cell Signaling 2008, 20(6):1198-208.
22. Ishdorj G, Graham BA, Hu X, Chen J, Johnston JB, Fang X, Gibson SB. Lysophosphatidic acid protects cancer cells from histone deacetylase (HDAC) inhibitor-induced apoptosis through activation of HDAC. Journal of Biological Chemistry 2008, 283(24):16818-29. 10.1074/jbc.M710177200, 2423270, 18408217.
23. Heasley LE, Han SY. JNK regulation of oncogenesis. Molecular Cells 2006, 21(2):167-73.
24. Jaeschke A, Karasarides M, Ventura JJ, Ehrhardt A, Zhang C, Flavell RA, Shokat KM, Davis RJ. JNK2 is a positive regulator of the cJun transcription factor. Molecular Cell 2006, 23(6):899-911. 10.1016/j.molcel.2006.07.028, 16973441.
25. Fuchs SY, Fried VA, Ronai Z. Stress-activated kinases regulate protein stability. Oncogene 1998, 17:1483-90. 10.1038/sj.onc.1202184, 9779995.
26. Lin TS, Mahajan S, Frank DA. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 2000, 19(21):2496-504. 10.1038/sj.onc.1203486, 10851048.
27. Kuida K, Boucher DM. Functions of MAP Kinases: Insights from Gene-Targeting Studies. J Biochem 2004, 135(6):653-656. 10.1093/jb/mvh078, 15213239.
28. Chung J, Uchida E, Grammer TC, Blenis J. STAT3 serine phosphorylation by ERK-dependent and-independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol 1997, 17(11):6508-16. 232504, 9343414.
29. Lim CP, Cao X. . Serine phosphorylation and negative regulation of Stat3 by JNK. J Biol Chem 1999, 274:31055-31061. 10.1074/jbc.274.43.31055, 10521505.
30. Nitta RT, Del Vecchio CA, Chu AH, Mitra SS, Godwin AK, Wong AJ. The role of the c-Jun N-terminal kinase 2-α-isoform in non-small cell lung carcinoma tumorigenesis. Oncogene 2011, 30(2):234-44. 10.1038/onc.2010.414, 20871632.
31. Kay NE, Bone ND, Tschumper RC, Howell KH, Geyer SM, Dewald GW, Hanson CA, Jelinek DF. B-CLL cells are capable of synthesis and secretion of both pro-and anti-angiogenic molecules. Leukemia 2002, 16(5):911-9. 10.1038/sj.leu.2402467, 11986954.
32. Lee YK, Shanafelt TD, Bone ND, Strege AK, Jelinek DF, Kay NE. VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance. Leukemia 2005, 19(4):513-23.
33. Krejsgaard T, Vetter-Kauczok CS, Woetmann A, Lovato P, Labuda T, Eriksen KW, Zhang Q, Becker JC, Ødum N. Jak3-and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia. 200 2006, 20(10):1759-66.
34. Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS. A central role for JNK in obesity and insulin resistance. Nature 2002, 420(6913):333-6. 10.1038/nature01137, 12447443.
35. Platanias L. Map kinase signaling pathways Map kinase signaling pathways and hematologic malignancies. Blood 2003, 101:4667-4679. 10.1182/blood-2002-12-3647, 12623839.
36. Berra E, Pagès G, Pouysségur J. MAP kinases and hypoxia in the control of VEGF expression. Cancer and Metastasis Reviews 2000, 19(1-2):139-45.
37. Guma M, Rius J, Duong-Polk KX, Haddad GG, Lindsey JD, Karin M. Genetic and pharmacological inhibition of JNK ameliorates hypoxia-induced retinopathy through interference with VEGF expression. Proceedings of the National Academy of Sciences 2009, 106(21):8760-5.
38. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature Reviews Cancer 2008, 8(8):579-91. 10.1038/nrc2403, 18596824.
39. Lev DC, Ruiz M, Mills L, McGary EC, Price JE, Bar-Eli M. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Molecular Cancer Therapeutics 2003, 2(8):753-63.
40. Solban N, Selbo PK, Sinha AK, Chang SK, Hasan T. Mechanistic investigation and implications of photodynamic therapy induction of vascular endothelial growth factor in prostate cancer. Cancer Research 2006, 66(11):5633-40. 10.1158/0008-5472.CAN-06-0604, 16740700.
41. Yano K, Kadoya K, Kajiya K, Hong YK, Detmar M. Ultraviolet B irradiation of human skin induces an angiogenic switch that is mediated by upregulation of vascular endothelial growth factor and by downregulation of thrombospondin-1. British Journal Dermatology 2005, 152(1):115-21.
42. Kraemer M, Tournaire R, Dejong V, Montreau N, Briane D, Derbin C, Binétruy B. Rat embryo fibroblasts transformed by c-Jun display highly metastatic and angiogenic activities in vivo and deregulate gene expression of both angiogenic and antiangiogenic factors. Cell Growth and Differentiation 1999, 10(3):193-200.